Mitsubishi Tanabe Pharma Corp. (MTP) has made the first approval filing globally, in Japan, for vadadustat (MT-6548), its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) licensed from US venture Akebia Therapeutics Inc.
The pioneering regulatory submission, if approved, is expected to lead to the first launch of the molecule worldwide. It also...







